These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1540881)

  • 1. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
    Laurie JA; Hahn RG; Therneau TM; Patel SR; Mailliard JA; Windschitl HE; Twito DI; Morton RF; Krook JE
    Cancer; 1992 Mar; 69(6):1440-4. PubMed ID: 1540881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ
    Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
    Park JO; Chung HC; Cho JY; Rha SY; You NC; Kim JH; Noh SH; Kim CB; Min JS; Kim BS; Roh JK
    Am J Clin Oncol; 1997 Oct; 20(5):484-9. PubMed ID: 9345333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
    Cocconi G; Bella M; Zironi S; Algeri R; Di Costanzo F; De Lisi V; Luppi G; Mazzocchi B; Rodinò C; Soldani M
    J Clin Oncol; 1994 Dec; 12(12):2687-93. PubMed ID: 7989945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
    Chang HM; Jung KH; Kim TY; Kim WS; Yang HK; Lee KU; Choe KJ; Heo DS; Bang YJ; Kim NK
    Ann Oncol; 2002 Nov; 13(11):1779-85. PubMed ID: 12419751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
    Kasimis BS; Miller JB; Kaneshiro CA; Forbes KA; Moran EM; Metter GE
    J Clin Oncol; 1985 Mar; 3(3):385-92. PubMed ID: 3838343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
    De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; Rodinò C; Soldani M; Tonato M; Finardi C
    Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
    Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
    Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
    Cullinan SA; Moertel CG; Fleming TR; Rubin JR; Krook JE; Everson LK; Windschitl HE; Twito DI; Marschke RF; Foley JF
    JAMA; 1985 Apr; 253(14):2061-7. PubMed ID: 2579257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
    Kasimis BS; Moran EM; Miller JB; Forbes KA; Kaneshiro CA; Poblet MT; Williams JL
    Cancer Treat Rep; 1983 Oct; 67(10):937-9. PubMed ID: 6688755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
    Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.
    Cullinan S; Moertel CG; Wieand HS; Schutt AJ; Krook JE; Foley JF; Norris BD; Kardinal CG; Tschetter LK; Barlow JF
    Cancer; 1990 May; 65(10):2207-12. PubMed ID: 2189551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the efficacy and toxicity of protocol cisplatin, 5-fluorouracil, leucovorin compared to protocol fluorouracil, doxorubicin and mitomycin C in locally advanced and metastatic gastric cancer].
    Andrić Z; Randjelović T; Kovčin V; Gutović J; Crevar S; Murtezani Z; Kostić S
    Srp Arh Celok Lek; 2012; 140(5-6):305-12. PubMed ID: 22826983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.
    Lim KH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ
    Oncology; 2012; 83(2):57-66. PubMed ID: 22760079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.
    Krook JE; Jett JR; Fleming TR; Dalton RJ; Marschke RF; Cullinan SA; Windschitl HE; Everson LK; Brunk FS; Laurie JA
    J Clin Oncol; 1985 Jun; 3(6):842-8. PubMed ID: 3839263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
    Blumenstein B; Crawford ED; Saiers JH; Stephens RL; Rivkin SE; Coltman CA
    J Urol; 1993 Aug; 150(2 Pt 1):411-3. PubMed ID: 8326565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.
    Goldberg RM; Smith FP; Ueno W; Ahlgren JD; Schein PS
    J Clin Oncol; 1986 Mar; 4(3):395-9. PubMed ID: 3754004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
    Gibson MK; Holcroft CA; Kvols LK; Haller D
    Oncologist; 2005 Feb; 10(2):132-7. PubMed ID: 15709215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial.
    Takada T; Nimura Y; Katoh H; Nagakawa T; Nakayama T; Matsushiro T; Amano H; Wada K
    Hepatogastroenterology; 1998; 45(24):2020-6. PubMed ID: 9951857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
    van der Gaast A; Verweij J; Planting AS; Stoter G
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):765-8. PubMed ID: 3383976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.